Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 5:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2233–2256 of 16,142 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin Disorders Clear all

Conditions: Dry Age-related Macular Degeneration, Geographic Atrophy, Retinal Disease, Macular Degeneration, Macular Atrophy, Retinal Degeneration, Eye Diseases
Interventions: Not listed
Lead sponsor: Complement Therapeutics; Industry
Eligibility: 65 Years and older
Enrollment: 234 participants
Timeline: 2023 – 2025
U.S. locations: 10
States / cities: Glendale, California • Mountain View, California • Carmel, Indiana + 7 more

Conditions: Breast Cancer
Interventions: questionaire, blood or saliva sample; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 54 Years · Female only
Enrollment: 1,699 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2027
U.S. locations: 4
States / cities: Stanford, California • Iowa City, Iowa • New York, New York + 1 more

Conditions: Malignant Melanoma
Interventions: ACY-241, nivolumab, ipilimumab; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Cartilage Disease
Interventions: Meniscus repair for red/white tears without PRP, Meniscus repair with PRP; Procedure
Lead sponsor: Sue Barber-Westin; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Scleroderma, Sclerodactyly, Systemic Sclerosis
Interventions: hyaluronidase; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Stanford, California

Conditions: Acne Keloidalis Nuchae
Interventions: Targeted UV-B; Radiation
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Rheumatoid Arthritis
Interventions: corticotrophin 80 units; Drug
Lead sponsor: Gaylis, Norman B., M.D.; Individual
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Aventura, Florida

Conditions: Anxiety Disorder, Breast Cancer, Depression, Fatigue, Hot Flashes, Pain, Sleep Disorders
Interventions: acupuncture therapy, sham intervention; Procedure
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older · Female only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)
Interventions: Not listed
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 38,396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Lawrenceville, New Jersey

Conditions: Primary Immune Thrombocytopenia
Interventions: Placebo, TAK-079; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 7
States / cities: Tucson, Arizona • Gainesville, Florida • Peoria, Illinois + 3 more

Conditions: Diabetic Foot, Diabetes Type 2 With Diabetic Ulcer of Toe, Skin Breakdown
Interventions: Real Time Continuous Glucose Monitoring (rt-CGM), Fingerstick blood glucose (FBG) monitoring, Diabetes Education; Device · Other · Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Atlanta, Georgia • Decatur, Georgia

Conditions: Breast Cancer
Interventions: Music; Behavioral
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Venous Thromboses, Venous Disease, Venous Leg Ulcer, Venous Stasis, Venous Ulcer, Venous Stenosis, Venous Occlusion, Vein Thrombosis, Vein Occlusion, Vein Disease
Interventions: GORE® VIAFORT Vascular Stent; Device
Lead sponsor: W.L.Gore & Associates; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 24
States / cities: Stanford, California • Darien, Connecticut • New Haven, Connecticut + 20 more

Conditions: Psoriasis
Interventions: Apremilast and Clobetasol; Combination Product
Lead sponsor: Washington Dermatology Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Diabetic Foot, Diabetic Foot Ulcer, Diabetes, Diabetes Mellitus, Infected Wound, Infected Ulcer of Skin
Interventions: Phototherapy, Debridement Surgery and Wound Dressing; Device · Procedure
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Lower Limb Amputation Below Knee, Diabetes (DM), Skin Temperature Change, Vascular Reactivity
Interventions: Warming stimulus starting at 30 C initial temperature, Warming stimulus starting at 32 C initial temperature, Warming stimulus starting at 34 C initial temperature, Warming stimulus starting at 35 C initial temperature, Cooling stimulus starting at 30 C initial temperature, Cooling stimulus starting at 32 C initial temperature, Cooling stimulus starting at 34 C initial temperature, Cooling stimulus starting at 35 C initial temperature; Other
Lead sponsor: VA Puget Sound Health Care System; Federal
Eligibility: 18 Years to 70 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Breast Cancer
Interventions: Panobinostat (LBH589); Drug
Lead sponsor: Tulane University Health Sciences Center; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Breast Cancer, Breast Neoplasm
Interventions: Self-Regulation Condition, Emotional Disclosure Condition; Behavioral
Lead sponsor: University of Houston; Other
Eligibility: 18 Years and older · Female only
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Los Angeles, California • Houston, Texas

Conditions: Hidradenitis Suppurativa
Interventions: Clindamycin & Rifampin, Clindamycin + Rifampin along with NdYag Laser treatment; Drug · Procedure
Lead sponsor: Henry Ford Health System; Other
Eligibility: 16 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Melanoma
Interventions: Belvarafenib, Cobimetinib, Nivolumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 8
States / cities: San Francisco, California • Aurora, Colorado • Iowa City, Iowa + 4 more

Conditions: Melanoma
Interventions: MDX-CTLA4 Antibody; Tyrosinase/gp100/MART-1 Peptides Melanoma Vaccine; Biological
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Ocular Rosacea
Interventions: lotilaner, Vehicle; Drug
Lead sponsor: Tarsus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Houston, Texas • Lynchburg, Virginia

Conditions: Malignant Breast Neoplasm, Malignant Colorectal Neoplasm, Malignant Pancreatic Neoplasm, Malignant Solid Neoplasm
Interventions: Computed Tomography, Fluorine F 18-fluoroazomycin Arabinoside, Positron Emission Tomography; Procedure · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Actinic Keratosis, Keratosis, Actinic, Keratosis
Interventions: BF-200 ALA and red light LED lamp; Combination Product
Lead sponsor: Biofrontera Bioscience GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 9
States / cities: Phoenix, Arizona • Greenwood Village, Colorado • Indianapolis, Indiana + 5 more

Search by objective public record fields.

Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study

Study of Radiation Exposure and Bilateral Breast Cancer

Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab

Assessment of Outcome of Meniscus Repair With or Without Platelet Rich Plasma

Hyaluronidase Injections for Sclerodactyly in Patients With Scleroderma

Treatment of Acne Keloidalis Nuchae (Razor Bumps Behind the Neck) Using UV Light Therapy

The Effect of Corticotrophin (ACTH) in Combination With Methotrexate in Newly Diagnosed Rheumatoid Arthritis Patients

Acupuncture in Reducing Muscle and Bone Symptoms in Women Receiving Letrozole, Exemestane, or Anastrozole for Stage 0, Stage I, Stage II, or Stage III Breast Cancer

A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish Database

A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia

CGM and DFU Healing Post-discharge

Music as a Perioperative Therapy in Breast Cancer Patients

The GORE® VIABAHN® FORTEGRA Venous Stent Iliofemoral Study

Apremilast in Combination With Clobetasol Spray for the Treatment of Plaque Psoriasis

Adjunctive Phototherapy Treatment of Infected Diabetic Ulcers

Skin Temperature Perception and Prosthetic Thermoregulation

ERB-B4 After Treatment With HDAC Inhibitor in ER+ Tamoxifen Refractory Breast Cancer

Health Benefits of Expressive Writing: Study One

Trial Comparing Efficacy of Treatments for Hidradenitis Suppurativa

A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.

Novel Adjuvants for Peptide-Based Melanoma Vaccines

Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE)

18F-Fluoroazomycin Arabinoside PET-CT in Diagnosing Solid Tumors in Patients

Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp